Recent Progress in Polymer Therapeutics as Nanomedicines - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 94

Table 4.4 Examples of polymer-drug conjugates in clinical trials

Company Application Trade

name
(clinical
status)

Polymer

Pfizer, Inc. Lung, breast

and colorectal
cancer

PK1,
FCE28068
(phase II)

HPMA copolymer-
doxorubicin

Pfizer, Inc. Hepatocellular

carcinoma

PK2,
FCE2806
(phase I)

HPMA copolymer-
doxorubicin-
galactosamine

Access
Pharmaceuticals,
Inc

Ovarian and
colorectal
cancer

ProLindac TM
(AP5346)
(phase II)

HPMA copolymer-diami-
nocyclohexaneplatinum

Mersana
Therapeutics,
Inc.

Non-small cell
lung cancer
and other
cancers

XMT-1001
(phase I)

Poly(1-hydroxymethylene
hydroxylmethyl formal)
(PHF)- Camptothecin
(CPT)

Cerulean
Pharma Inc.

Ovarian
cancer and
other cancers

CRLX-
101(IT-101)
(phase I/II)

Cyclodextrin-
Camptothecin (CPT)

Cell therapeutics,
Inc.

Colorectal and
ovarian cancer

CT-2106
(phase I/II)

PGA-Camptothecin (CPT)

Cell therapeutics,
Inc.

Non-small cell
lung cancer
and ovarian
cancer

OPAXIO™
(paclitaxel
poliglumex,
CT-2103;
XYOTAX)
(phase III)

PGA-Paclitaxel

Nektar Opioid bowel

dysfunction
(OBD), and
opioid-
induced
constipation
(OIC).

NKTR-118
(phase II)

PEG-naloxol